155 related articles for article (PubMed ID: 34912479)
1. Use of [
Glover M; Caplin M; Leeuwenkamp OR; Longworth L
EJC Suppl; 2021 Nov; 16():14-23. PubMed ID: 34912479
[TBL] [Abstract][Full Text] [Related]
2. [
Spada F; Campana D; Lamberti G; Laudicella R; Dellamano R; Dellamano L; Leeuwenkamp O; Baldari S
Eur J Nucl Med Mol Imaging; 2022 May; 49(6):2037-2048. PubMed ID: 34950969
[TBL] [Abstract][Full Text] [Related]
3. Matching-adjusted indirect treatment comparison of [
Khan MS; Stamp E; Sammon C; Brabander T; de Herder WW; Pavel ME
EJC Suppl; 2021 Nov; 16():5-13. PubMed ID: 34912478
[TBL] [Abstract][Full Text] [Related]
4. Everolimus, lutetium-177 DOTATATE and sunitinib for advanced, unresectable or metastatic neuroendocrine tumours with disease progression: a systematic review and cost-effectiveness analysis.
Mujica-Mota R; Varley-Campbell J; Tikhonova I; Cooper C; Griffin E; Haasova M; Peters J; Lucherini S; Talens-Bou J; Long L; Sherriff D; Napier M; Ramage J; Hoyle M
Health Technol Assess; 2018 Sep; 22(49):1-326. PubMed ID: 30209002
[TBL] [Abstract][Full Text] [Related]
5. Lutetium oxodotreotide (
Smith-Palmer J; Leeuwenkamp OR; Virk J; Reed N
BMC Cancer; 2021 Jan; 21(1):10. PubMed ID: 33402120
[TBL] [Abstract][Full Text] [Related]
6. Real-world comparison of healthcare resource utilization and costs of [
Cox T; O'Connell M; Leeuwenkamp O; Palimaka S; Reed N
Curr Med Res Opin; 2022 Aug; 38(8):1305-1317. PubMed ID: 35418254
[TBL] [Abstract][Full Text] [Related]
7. Lutetium [
Lastoria S; Rodari M; Sansovini M; Baldari S; D'Agostini A; Cervino AR; Filice A; Salgarello M; Perotti G; Nieri A; Campana D; Pellerito RE; Pomposelli E; Gaudieri V; Storto G; Grana CM; Signore A; Boni G; Dondi F; Simontacchi G; Seregni E
Eur J Nucl Med Mol Imaging; 2024 May; ():. PubMed ID: 38772998
[TBL] [Abstract][Full Text] [Related]
8. Cost-effectiveness of lutetium (
Palmer J; Leeuwenkamp OR
World J Clin Cases; 2020 Oct; 8(20):4793-4806. PubMed ID: 33195647
[TBL] [Abstract][Full Text] [Related]
9. Cost-effectiveness of Lutetium [
Leeuwenkamp O; Smith-Palmer J; Ortiz R; Werner A; Valentine W; Blachier M; Walter T
J Med Econ; 2020 Dec; 23(12):1534-1541. PubMed ID: 32990484
[TBL] [Abstract][Full Text] [Related]
10. Toxicity of a combined therapy using the mTOR-inhibitor everolimus and PRRT with [
Zellmer J; Yen HY; Kaiser L; Mille E; Gildehaus FJ; Böning G; Steiger K; Hacker M; Bartenstein P; Todica A; Haug AR; Ilhan H
EJNMMI Res; 2020 Apr; 10(1):41. PubMed ID: 32335736
[TBL] [Abstract][Full Text] [Related]
11. Safety, Pharmacokinetics, and Dosimetry of a Long-Acting Radiolabeled Somatostatin Analog
Zhang J; Wang H; Jacobson O; Cheng Y; Niu G; Li F; Bai C; Zhu Z; Chen X
J Nucl Med; 2018 Nov; 59(11):1699-1705. PubMed ID: 29653971
[TBL] [Abstract][Full Text] [Related]
12. Efficacy and Safety of [
Hertelendi M; Belguenani O; Cherfi A; Folitar I; Kollar G; Polack BD
Biomedicines; 2023 Mar; 11(4):. PubMed ID: 37189646
[TBL] [Abstract][Full Text] [Related]
13. Epidemiology of Neuroendocrine Neoplasms and Results of Their Treatment with [
Durma AD; Saracyn M; Kołodziej M; Jóźwik-Plebanek K; Dmochowska B; Kapusta W; Żmudzki W; Mróz A; Kos-Kudła B; Kamiński G
Cancers (Basel); 2023 Nov; 15(22):. PubMed ID: 38001726
[TBL] [Abstract][Full Text] [Related]
14. Prediction of [
Ha S; Kim YI; Oh JS; Yoo C; Ryoo BY; Ryu JS
EJNMMI Phys; 2024 Feb; 11(1):14. PubMed ID: 38315270
[TBL] [Abstract][Full Text] [Related]
15. Comparison of sequential planar 177Lu-DOTA-TATE dosimetry scans with 68Ga-DOTA-TATE PET/CT images in patients with metastasized neuroendocrine tumours undergoing peptide receptor radionuclide therapy.
Sainz-Esteban A; Prasad V; Schuchardt C; Zachert C; Carril JM; Baum RP
Eur J Nucl Med Mol Imaging; 2012 Mar; 39(3):501-11. PubMed ID: 22183108
[TBL] [Abstract][Full Text] [Related]
16. Estimation of Absorbed Doses of Indigenously Produced "Direct-route" Lutetium-177-[
Kamaldeep ; Loharkar S; Das T; Basu S; Banerjee S
Cancer Biother Radiopharm; 2022 Apr; 37(3):214-225. PubMed ID: 34910891
[No Abstract] [Full Text] [Related]
17. Evaluation of the Efficacy of a Combined Treatment Using the mTOR-Inhibitor Everolimus and [177Lu]Lu-DOTA-TATE in Nude CD1 Mice with SSTR-Expressing Pancreatic AR42J Xenograft Tumors.
Zellmer J; Yen HY; Kaiser L; Gildehaus FJ; Böning G; Steiger K; Hacker M; Bartenstein P; Todica A; Haug AR; Ilhan H
Biomedicines; 2022 Dec; 10(12):. PubMed ID: 36551858
[TBL] [Abstract][Full Text] [Related]
18. Relationships between uptake of [
Stenvall A; Gustafsson J; Larsson E; Roth D; Sundlöv A; Jönsson L; Hindorf C; Ohlsson T; Sjögreen Gleisner K
EJNMMI Res; 2022 Dec; 12(1):75. PubMed ID: 36534192
[TBL] [Abstract][Full Text] [Related]
19. Overcoming nephrotoxicity in peptide receptor radionuclide therapy using [
Geenen L; Nonnekens J; Konijnenberg M; Baatout S; De Jong M; Aerts A
Nucl Med Biol; 2021; 102-103():1-11. PubMed ID: 34242948
[TBL] [Abstract][Full Text] [Related]
20. Treatment with tandem [90Y]DOTA-TATE and [177Lu]DOTA-TATE of neuroendocrine tumours refractory to conventional therapy.
Seregni E; Maccauro M; Chiesa C; Mariani L; Pascali C; Mazzaferro V; De Braud F; Buzzoni R; Milione M; Lorenzoni A; Bogni A; Coliva A; Lo Vullo S; Bombardieri E
Eur J Nucl Med Mol Imaging; 2014 Feb; 41(2):223-30. PubMed ID: 24233003
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
